Nano-drug with anticancer activity as well as preparation method and application of nano-drug
The nanodrug formed by loading nanogold and glucose oxidase on the titanium carbide carrier and combining nanomanganese dioxide and human serum protein-folate composite materials to target nanomedicine, the poor therapeutic effect of glucose oxidase in the prior art was solved. Problem, achieving efficient tumor cell killing and improving therapeutic effect.
Patent Information
- Application Number
- CN202411211786.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-22
AI Technical Summary
The existing targeted glucose oxidase therapy has not had significant enough killing effects on tumor cells, and it has systemic toxicity and stability problems. The effect of single drug treatment is limited and cannot effectively improve the effect of glucose oxidase in cancer cell starvation treatment.
Using titanium carbide (Ti3C2) carrier to load nanogold and glucose oxidase, combined with nanomanganese dioxide and human serum protein-folate composite materials, to form a two-dimensional flake-like structure, combining photothermal conversion and starvation treatment , improve the mortality rate of tumor cells.
It significantly improves the mortality rate of tumor cells, enhances the targeting and biocompatibility of drugs, improves the therapeutic effect under synergy, and achieves more efficient anti-cancer activity.
Smart Images

Figure CN118987255A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical fields of material chemistry and biomedical engineering, and more specifically, to a nano drug with anti-cancer activity and a preparation method and application thereof. Background Art
[0002] Since glucose is indispensable for tumor growth, cancer starvation therapy based on glucose deprivation has attracted widespread attention in recent years. Studies have shown that glucose oxidase catalyzes the reaction of glucose and oxygen to form gluconic acid and hydrogen peroxide, and is a powerful tool for starving tumor cells. However, the poor efficacy of single drug therapy targeting glucose metabolism and the severe systemic toxicity and poor stability of glucose oxidase have limited the clinical application of glucose oxidase.
[0003] Although existing drug-carrying materials have improved their anti-cancer activity by increasing cell targeting and enriching the drug-carrying materials in cancer cells, they are still unable to further improve the starvation therapy effect of cells, and the mortality rate of tumor cells is low. Summary of the invention
[0004] The present application is provided to solve the above-mentioned defects existing in the prior art. A nano drug with anti-cancer activity and its preparation method and application are needed, and a nano drug for cancer cells is provided, which can not only serve as the basic performance of a drug carrier, but also further improve the effect of glucose oxidase in starvation treatment of cancer cells and increase the mortality rate of tumor cells.
[0005] In a first aspect of the present application, a nanomedicine with anti-cancer activity is provided, wherein the nanomedicine comprises a titanium carbide carrier (Ti3C2) and targeted nanomaterials, nanogold and glucose oxidase loaded on the Ti3C2 carrier, wherein the titanium carbide carrier is a two-dimensional sheet structure, and the targeted nanoparticle material comprises nanomanganese dioxide, human serum albumin and folic acid, wherein the human serum albumin is modified on the surface of the nanomanganese dioxide and connected to folic acid molecules to form spherical particles, the nanogold and manganese dioxide targeted nanoparticles are loaded on the surface of the titanium carbide, and the glucose oxidase is wrapped in the outermost layer of the material.
[0006] In some embodiments, the particle size of the gold nanoparticles is 5-10 nm.
[0007] In some embodiments, the targeted nanoparticle material has a particle size of 20-50 nm.
[0008] In some embodiments, the mass ratio of titanium carbide, glucose oxidase, manganese dioxide-human serum albumin-folic acid, and nano-gold is 1-5 mg: 0.005-0.015 mg: 0.1-0.5 mg: 0.236 mg – 4.74 mg. Preferably, the mass ratio of titanium carbide, glucose oxidase, manganese dioxide-human serum albumin-folic acid, and nano-gold is 1-4 mg: 0.008-0.01 mg: 0.1-0.4 mg: 4.5 mg.
[0009] In a second aspect of the present application, a method for preparing a nano drug with anti-cancer activity as described in any embodiment of the present application is provided, the preparation method comprising: mixing a titanium carbide carrier with a nano gold solution, glucose oxidase, a targeted nano particle material and deionized water at room temperature to obtain a nano drug carrier material.
[0010] In some embodiments, the mass volume ratio of the titanium carbide carrier, glucose oxidase, targeted nanoparticle material, nanogold solution and deionized water is 1-4 mg: 0.008-0.01 mg: 0.1-0.4 mg: 0.5-10 mL: 0.5-10 mL.
[0011] In some embodiments, during the preparation process, the titanium carbide carrier can be first dissolved in water, and then the nano-gold solution, glucose oxidase, and targeted nano-particle material are added in sequence. Alternatively, the nano-gold solution is first diluted with water, and then the titanium carbide carrier, glucose oxidase, and targeted nano-particle material are added in sequence.
[0012] In some embodiments, the preparation method of the titanium carbide carrier includes: at room temperature, MAX phase titanium aluminum carbide (Ti3AlC2) is first soaked in a hydrochloric acid solution for pretreatment, then a hydrogen fluoride solution is added and stirred evenly, and the mixed solution is transferred to a polytetrafluoroethylene reactor for reaction under heating conditions. The product after the reaction is separated to obtain a precipitate A; the precipitate A is mixed with dimethyl sulfoxide to obtain a titanium carbide carrier after the reaction.
[0013] In some embodiments, the pretreatment time of Ti3AlC2 is 0.5-3 h, preferably 1-2 h.
[0014] In some embodiments, the mixed solution is transferred to a polytetrafluoroethylene reactor and reacted at 60-100°C.
[0015] In some embodiments, the corresponding reaction time in a polytetrafluoroethylene reactor is 5-12 h.
[0016] In some embodiments, the concentration of the hydrogen fluoride solution is 20-25 mol / L, the concentration of the hydrochloric acid solution is 30-35 mol / L, and the volume ratio of the hydrogen fluoride solution to the hydrochloric acid solution is 1:0.8-3; preferably, the volume ratio of the hydrogen fluoride solution to the hydrochloric acid solution is 1:1-1.2. Preferably, the concentration of the hydrogen fluoride solution is 22 mol / L, 22.6 mol / L, 23 mol / L, etc., and the concentration of the hydrochloric acid solution is 30 mol / L, 31.7 mol / L, 33 mol / L, etc.
[0017] In some embodiments, the ratio of Ti3AlC2 to hydrogen fluoride solution and hydrochloric acid solution is: 0.5-1 g: 5-15 mL: 5-15 mL. In some embodiments, the reaction time of Ti3AlC2 and the mixed solution of hydrogen fluoride and hydrochloric acid is 5-12 h, preferably 6-10 h, so as to achieve a sufficient mixing reaction of Ti3AlC2 and the acid.
[0018] In some embodiments, the mass volume ratio of precipitate A to dimethyl sulfoxide is 0.5 g-1 g: 20-40 mL. In some embodiments, the reaction time of precipitate A and dimethyl sulfoxide is 15-40 h; preferably, the reaction time is 20-30 h.
[0019] In some embodiments, the preparation method of the targeted nanoparticle material includes: mixing potassium permanganate solution and human serum protein solution, reacting under alkaline conditions to obtain a mixed solution A; dialyzing the mixed solution A with water to obtain a mixed solution B; drying the mixed solution B to obtain a composite material of manganese dioxide and human serum protein; mixing the aqueous solution of the composite material of manganese dioxide and human serum protein with a folic acid active ester (Fa-NHS, folic acid-N-hydroxysuccinimide) solution to obtain a mixed solution C; dialyzing the mixed solution C with water to obtain a mixed solution D; and drying the mixed solution D to obtain the targeted nanoparticle material. The targeted nanoparticles are prepared by the above-mentioned biomineralization method, so that human serum protein and folic acid are combined with manganese dioxide.
[0020] In some embodiments, the active ester of folic acid (Fa-NHS, folic acid-N-hydroxysuccinimide) is obtained by the following method: a dimethyl sulfoxide (DMSO) solution of folic acid (Fa) is mixed with 1-ethyl-(3-dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS), and triethylamine (TEA), and reacted under light-proof conditions to obtain a Fa-NHS solution. The mass volume ratio of Fa, DMSO, EDC, NHS, and TEA is: 5-15 mg: 5-15 mL: 15-25 mg: 15-25 mg: 45-55 µL. Preferably, 10 mg: 10 mL: 20 mg: 20 mg: 50 µL.
[0021] In some implementations, the concentration of the potassium permanganate solution is 5-10 mg / mL, the concentration of the human serum albumin solution is 20-30 mg / mL, and the volume ratio of the potassium permanganate solution to the human serum albumin solution is 1:1-3; preferably, the concentration of the potassium permanganate solution is 6-8 mg / mL, and the concentration of the human serum albumin solution is 23-28 mg / mL.
[0022] In some embodiments, sodium hydroxide is used to adjust to alkaline conditions. In some embodiments, the alkaline conditions are pH 9-11, such as 10, 10.5, etc.
[0023] In some embodiments, the potassium permanganate solution and human serum albumin are reacted under alkaline conditions for 5-20 min. Preferably, the reaction time is 3-10 min.
[0024] In some embodiments, the water dialysis time is 20-40 h. The corresponding water dialysis time is obtained according to the capacity of the water dialysis bag and the volume of the solution. In some embodiments, the drying can be freeze drying.
[0025] In some embodiments, the concentration of the aqueous solution of the composite material of manganese dioxide and human serum albumin is 1-3 mg / mL, the concentration of the Fa-NHS solution is 0.1-0.5 mg / mL, and the volume ratio of the aqueous solution of the composite material to the Fa-NHS solution is 2-5: 1. Preferably, the concentration of the aqueous solution of the composite material of manganese dioxide and human serum albumin is 2-2.5 mg / mL, the concentration of the folic acid active ester solution is 0.1-0.3 mg / mL, and the volume ratio of the aqueous solution of the composite material to the folic acid active ester solution is 2-4: 1.
[0026] In some embodiments, the water dialysis process includes dialysis of the obtained mixed solution C with PBS solution (0.01 mol / L) and water, respectively, wherein the volume of the PBS solution and the volume of the water are respectively twice the volume of the mixed solution C. The dialysis time is 2-4 days. The dialysis time can be determined according to the volume of the dialysis bag and the volume of the mixed solution C.
[0027] In some embodiments, the method for preparing the nano-gold solution includes: mixing a chloroauric acid solution with a mixed solution E of sodium borohydride and polyvinyl pyrrolidone, and reacting under heating conditions to obtain the nano-gold solution.
[0028] In some embodiments, the volume ratio of the chloroauric acid solution to the mixed solution E is 5-1:1; preferably, the volume ratio is 4-2:1. The concentration of the chloroauric acid solution is 0.002-0.003 mol / L. In the mixed solution E, the concentrations of sodium borohydride and polyvinyl pyrrolidone are 0.003-0.06 mg / mL, respectively.
[0029] In some embodiments, the reaction time of the chloroauric acid solution and the mixed solution E after heating is 1-10 min; preferably, the reaction time is 1-5 min.
[0030] According to the third aspect of the present application, there is provided a nanomedicine with anti-cancer activity as described in any embodiment of the present application or a method for preparing the nanomedicine with anti-cancer activity as described in any embodiment of the present application for use in anti-cancer drugs.
[0031] In the fourth aspect of the present application, an anticancer drug is provided, which includes the nanodrug with anticancer activity described in any embodiment of the present application and a drug component loaded on the nanodrug, and the drug component includes a mixture of one or more drugs such as paclitaxel, camptothecin, doxorubicin, vinblastine, cisplatin, carboplatin, methotrexate, daunorubicin, interleukin, interferon, growth factor and tumor necrosis factor.
[0032] The anticancer drug described in any embodiment of the present application can be used to treat a variety of diseases such as gastric cancer, ovarian cancer, breast cancer, liver cancer and bladder cancer. The anticancer drug can also be used to treat a variety of cancer diseases, and the type of active pharmaceutical ingredients in the anticancer drug can be changed to make it more suitable for the treatment of a variety of diseases.
[0033] The nanomedicines with anti-cancer activity, their preparation methods and applications provided in various embodiments of the present application have a titanium carbide carrier with a two-dimensional sheet structure that can provide more loading sites; the targeted particle material can improve the targeting and biocompatibility of the nano-drug carrier material; through the combination of nanogold and glucose oxidase, the nanogold has peroxidase-like properties and photothermal conversion performance, which can improve the effect of starvation therapy and photothermal therapy, and synergistically improve the mortality rate of tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] In the drawings, which are not necessarily drawn to scale, the same reference numerals may describe similar parts in different views. The same reference numerals with letter suffixes or different letter suffixes may represent different instances of similar parts. The accompanying drawings generally illustrate various embodiments by way of example and not limitation, and together with the specification and claims, are used to illustrate the embodiments applied for. When appropriate, the same reference numerals are used throughout the drawings to refer to the same or similar parts. Such embodiments are illustrative and are not intended to be exhaustive or exclusive embodiments of the present apparatus or method.
[0035] Figure 1 A transmission electron microscope image of titanium carbide-glucose oxidase-gold-manganese dioxide (TGAM) prepared in Example 1 of the present application is shown; Figure 2 The infrared spectra of titanium carbide (Ti3C2), glucose oxidase (GOx), gold (Au), manganese dioxide-human serum albumin-folic acid (MHF) and TGAM prepared in Example 1 of the present application are shown; Figure 3 The UV spectra of GOx, Au, MHF and TGAM prepared in Example 1 of the present application are shown; Figure 4 The dispersion diagram of Ti3C2, Au, GOx and TGAM prepared in Example 1 of the present application in deionized water is shown; Figure 5 It shows that Ti3C2, Au and TGAM prepared in Example 1 of the present application are at 808 nm (power is 1.5 W / cm 2 ) Statistical graph of photothermal data under near-infrared light irradiation; Figure 6 A statistical graph showing the cell survival rates of A549 cells and HeLa cells of the present application when cultured with Ti3C2 prepared in Example 1 at different concentrations; Figure 7 The cell survival rate statistics of A549 cells and HeLa cells of the present application after being cultured with TGAM prepared in Example 1 for 24 hours are shown; Figure 8 The results show that the HeLa cells of the present invention were cultured with GOx, pure Ti3C2, TGM, TGAM prepared in Example 1, and cultured with 808 nm (power of 2.6 W / cm 2 ) Statistical graph of cell survival rate after 24 h of culture under near-infrared light irradiation. DETAILED DESCRIPTION
[0036] In order to enable those skilled in the art to better understand the technical solution of the present application, the present application is described in detail below in conjunction with the accompanying drawings and specific implementation examples. The embodiments of the present application are further described in detail below in conjunction with the accompanying drawings and specific implementation examples, but are not intended to limit the present application.
[0037] The words "first", "second" and similar words used in this application do not indicate any order, quantity or importance, but are only used to distinguish. The words "include" or "comprise" and similar words mean that the elements before the word include the elements listed after the word, and do not exclude the possibility of including other elements.
[0038] According to an embodiment of the present application, a nanomedicine with anti-cancer activity is also provided, wherein the nanomedicine includes a Ti3C2 carrier and targeted nanomaterials, nano-Au and GOx loaded on the Ti3C2 carrier, wherein the Ti3C2 carrier is a two-dimensional sheet structure, and the targeted nanoparticle material includes nano manganese dioxide (MnO2), human serum albumin (HSA) and folic acid (Fa), HSA is modified on the surface of nano-MnO2 and connected to folic acid molecules to form spherical particles, nano-Au and MnO2 targeted nanoparticles are loaded on the surface of Ti3C2, and GOx is wrapped in the outermost layer of the material.
[0039] Ti3C2 exhibits strong absorption and excellent histological penetration in the near-infrared (NIR) region and can be used as a photothermal medium for tumor treatment. Due to the two-dimensional sheet structure of Ti3C2, GOx and other small particle nanomaterials can be effectively loaded. Therefore, Ti3C2 can be used as an effective carrier for combined photothermal therapy and starvation therapy to kill cancer cells.
[0040] GOx is loaded on the Ti3C2 carrier. GOx can specifically and efficiently catalyze the oxidation of glucose to produce gluconic acid and hydrogen peroxide, so it can consume the glucose in the tumor, thereby cutting off the energy supply of the tumor and achieving starvation therapy. However, in the tumor environment, the self-regulatory function of tumor cells will limit cell starvation therapy, so relying solely on GOx cannot achieve the goal of killing cancer cells.
[0041] Nano-MnO2 can consume glutathione in cancer cells. Reduced glutathione content in cancer cells can make cells more susceptible to oxidative stress, thereby effectively improving the effect of starvation therapy. After the folic acid in the targeted nanoparticle material specifically recognizes the folic acid receptor on the surface of cancer cells, the nano-drug carrier material can enter the cancer cells. In the tumor microenvironment, the targeted nanoparticle material can responsively release MnO2 to reduce the glutathione level in cancer cells. The synthesis of MnO2-HSA-Fa (MHF) by modifying HSA and Fa targeting molecules on the surface of MnO2 by biomineralization can not only solve the problem of poor water solubility of MnO2, but also make the material targeted and improve the utilization rate of drugs.
[0042] Nano-Au has catalytic activity that can promote the production of reactive oxygen species in tumor cells, and also has excellent photothermal conversion ability. The production of reactive oxygen species helps assist GOx in starvation therapy, and by utilizing its excellent photothermal conversion ability, it can absorb light and convert it into heat energy to increase the mortality rate of cancer cells.
[0043] The overall nano drug delivery material is in the nanoparticle size range, and the nano material can be enriched at the lesion site, so the nano drug delivery material of the present application can help improve the therapeutic effect of cancer cells.
[0044] The various components of the nano drug delivery material of the present application have a coordinated effect on each other. Ti3C2 itself plays the role of a carrier, but its water solubility is poor. After the Ti3C2 carrier is loaded with GOx and nano-Au, the nano drug delivery material has water solubility and stability in water.
[0045] Therefore, the nano drug delivery material of the present application has good biocompatibility and targeting. Based on the characteristics of nano materials and targeting, the nano drug delivery material can be aggregated in the tumor; it can not only aggregate in tumor cells, but also exert certain anti-cancer activity, which is reflected in the effective reduction of the energy supply of the tumor, and can also increase the influence of GOx on the tumor cells under the action of nano MnO2 consuming glutathione; and under the action of nano Au, it can provide the oxygen required by GOx, and can also use the photothermal conversion performance to damage the tumor tissue. The Ti3C2 carrier, targeted nanoparticle material, nano Au and GOx in the nano drug delivery material of the present application work synergistically, which is conducive to improving the therapeutic effect on tumor cells.
[0046] The nano drug-carrying material of the present application not only plays the role of a drug carrier, but also plays an anti-cancer role, can inhibit the activity of cancer cells or kill cancer cells, and as a drug carrier, can also carry other anti-cancer drugs, and can itself have the carrier effect of targeted drug delivery and drug sustained release. As an anti-cancer drug, it can greatly increase the mortality rate of tumor cells by combining starvation therapy and photothermal therapy.
[0047] In some embodiments, the particle size of the nano-Au is 5-10 nm.
[0048] In some embodiments, the targeted nanoparticle material has a particle size of 20-50 nm.
[0049] In some embodiments, in some embodiments, the mass volume ratio of Ti3C2, GOx, MHF, nano-Au and deionized water is 1-5 mg: 0.005-0.015 mg: 0.1-0.5 mg: 0.236 mg – 4.74 mg: 0.5-10 mL. Preferably, the mass volume ratio of Ti3C2, GOx, MHF, nano-Au and deionized water is 1-5 mg: 0.005-0.015 mg: 0.1-0.5 mg: 4.5 mg: 0.5-10 mL.
[0050] According to the embodiments of the present application, there is also provided a method for preparing the nanomedicine with anti-cancer activity as described in any embodiment of the present application, the preparation method comprising: mixing and reacting a Ti3C2 carrier with a nano-Au solution, GOx, a targeted nanoparticle material and water at room temperature to obtain a nano-drug carrier material.
[0051] In some embodiments, the mass volume ratio of the Ti3C2 carrier, GOx, targeted nanoparticle material, nano-Au solution and deionized water is 1-4 mg: 0.008-0.01 mg: 0.1-0.4 mg: 0.5-10 mL: 0-5 mL, wherein the concentration of the nano-Au solution is 0.02-0.03 mol / L. Preferably, the concentration of the nano-Au solution is 0.024 mol / L.
[0052] In some embodiments, during the preparation process, the Ti3C2 carrier can be first dissolved in water, and then the nano-Au solution, GOx, and targeted nano-particle material are added in sequence. Or the nano-Au solution is first diluted with water, and then the Ti3C2 carrier, GOx, and targeted nano-particle material are added in sequence. And each raw material can be ultrasonically treated when added to better dissolve, and the dissolution and stirring time can be different, for example, 10-30 h. After the mixing reaction, the precipitate is washed and then freeze-dried to obtain a nano drug-carrying material.
[0053] In some embodiments, the preparation method of the Ti3C2 carrier includes: at room temperature, immersing the MAX phase Ti3AlC2 in a hydrochloric acid (HCl) solution for pretreatment, then adding a hydrogen fluoride (HF) solution and stirring evenly, transferring the mixed solution to a polytetrafluoroethylene reactor and reacting under heating conditions. The product after the reaction is separated to obtain a precipitate A; the precipitate A is mixed with dimethyl sulfoxide (DMSO) to obtain a Ti3C2 carrier after the reaction. The precipitate A can be washed with water; the washing can be assisted by ultrasonic operation to improve the washing effect of the precipitate A. The precipitate B obtained by mixing the precipitate A with DMSO in the solution is a Ti3C2 carrier, and the precipitate B is separated from the solution. At this time, some substances in the solution remain on the surface of the precipitate B. The precipitate B is washed with water, and then the precipitate B is separated by centrifugation, and then freeze-dried to obtain the Ti3C2 carrier.
[0054] The MAX phase Ti3AlC2 is a layered compound, and microscopically Ti3AlC2 has a hexagonal crystal structure. The MAX phase Ti3AlC2 is used as a precursor to form a two-dimensional sheet material after acid etching.
[0055] In some embodiments, the preparation method of the Ti3C2 carrier includes: at room temperature, Ti3AlC2 is first soaked in HCl solution for pretreatment, then HF solution is added and stirred evenly, and the mixed solution is transferred to a polytetrafluoroethylene reactor for reaction under heating conditions. The product after the reaction is separated to obtain a precipitate A; the precipitate A is mixed with DMSO to obtain a Ti3C2 carrier after reaction.
[0056] In some embodiments, the pretreatment time of Ti3AlC2 is 0.5-3 h, preferably 1-2 h, which is beneficial to the full dissolution of Ti3AlC2 and facilitates the subsequent acid etching.
[0057] In some embodiments, the mixed solution is transferred to a polytetrafluoroethylene reactor and reacted at 60-100°C.
[0058] In some embodiments, the corresponding reaction time in the polytetrafluoroethylene reactor is 5-12 h, preferably 6-10 h, so as to achieve a sufficient mixing reaction between Ti3AlC2 and the acid and complete etching of Al by HF.
[0059] In some embodiments, the concentration of the HF solution is 20-25 mol / L, the concentration of the HCl solution is 30-35 mol / L, and the volume ratio of the HF solution to the HCl solution is 1:0.8-3; preferably, the volume ratio of the HF solution to the HCl solution is 1:1-1.2.
[0060] In some embodiments, the ratio of Ti3AlC2 to HF solution and HCl solution is: 0.5-1 g: 5-15 mL: 5-15 mL.
[0061] In some embodiments, the preparation method of the targeted nanoparticle material includes: mixing potassium permanganate (KMnO4) solution and HSA solution, reacting under alkaline conditions to obtain a mixed solution A; dialyzing the mixed solution A with water to obtain a mixed solution B; drying the mixed solution B to obtain a composite material of MnO2 and HSA; mixing the aqueous solution of the composite material of MnO2 and HSA with a folic acid active ester (Fa-NHS, folic acid-N-hydroxysuccinimide) solution to obtain a mixed solution C; dialyzing the mixed solution C with water to obtain a mixed solution D; and drying the mixed solution D to obtain the targeted nanoparticle material. The targeted nanoparticles are prepared by the above-mentioned biomineralization method, so that HSA and Fa are combined with MnO2.
[0062] Under alkaline conditions, KMnO4 generates MnO2. During the generation process of MnO2, HSA is modified on the surface of MnO2. After mixing with Fa-NHS, HSA is connected with Fa, so that nanoparticles are formed as a whole.
[0063] In some embodiments, Fa-NHS is obtained by the following method: a DMSO solution of Fa is mixed with 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), and triethylamine (TEA), and reacted under light-proof conditions to obtain a Fa-NHS solution. The mass volume ratio of Fa, di-DMSO, EDC, NHS, and TEA is: 5-15 mg: 5-15 mL: 15-25 mg: 15-25 mg: 45-55 μL. Preferably, 10 mg: 10 mL: 20 mg: 20 mg: 50 μL.
[0064] In some embodiments, the concentration of the KMnO4 solution is 5-10 mg / mL, and the concentration of the HSA solution is 20-30 mg / mL; preferably, the concentration of the KMnO4 solution is 6-8 mg / mL, and the concentration of the HSA solution is 23-28 mg / mL, respectively.
[0065] In some embodiments, sodium hydroxide is used to adjust to alkaline conditions. In some embodiments, the alkaline conditions are pH 9-11, such as 10, 10.5, etc.
[0066] In some embodiments, the KMnO4 solution and the HAS solution are reacted under alkaline conditions for 5-20 min. Preferably, the reaction time is 8-15 min.
[0067] In some embodiments, the water dialysis time is 20-40 h. The corresponding water dialysis time is obtained according to the capacity of the water dialysis bag and the volume of the solution. In some embodiments, the drying can be freeze drying.
[0068] In some embodiments, the concentration of the aqueous solution of the composite material of MnO2 and HSA is 1-3 mg / mL, the concentration of the Fa-NHS solution is 0.1-0.5 mg / mL, and the volume ratio of the aqueous solution of the composite material to the Fa-NHS solution is 2-5: 1. Preferably, the concentration of the aqueous solution of the composite material of MnO2 and HSA is 2-2.5 mg / mL, the concentration of Fa-NHS is 0.1-0.3 mg / mL, and the volume ratio of the aqueous solution of the composite material to the Fa-NHS solution is 2-4: 1.
[0069] In some embodiments, the water dialysis process includes dialysis of the obtained mixed solution C with PBS solution (0.01 mol / L) and water, respectively, wherein the volume of the PBS solution and the volume of the water are respectively twice the volume of the mixed solution C. The dialysis time is 2-4 days. The dialysis time can be determined according to the volume of the dialysis bag and the volume of the mixed solution C.
[0070] In some embodiments, the preparation method of the nano Au solution includes: adding chloroauric acid solution (HAuCl4•4H2O) to a mixed solution E of sodium borohydride (NaBH4) and polyvinyl pyrrolidone (PVP), and reacting under heating conditions to obtain the nano Au solution.
[0071] In some embodiments, the volume ratio of HAuCl4•4H2O to the mixed solution E is 5-1:1; preferably, the volume ratio is 4-2:1. The concentration of HAuCl4•4H2O is 0.002-0.003 mol / L; preferably, the concentration of HAuCl4•4H2O is 0.002-0.0025 mol / L. In the mixed solution E, the concentrations of NaBH4 and PVP are 0.003-0.6 mg / mL, respectively; preferably, 0.003-0.5 mg / mL, such as 0.04 mg / mL, 0.48 mg / mL, etc.
[0072] In some embodiments, the reaction time of HAuCl4•4H2O and the mixed solution E after heating is 1-10 min; preferably, the reaction time is 1-5 min. PVP in the mixed solution E is used as a protective agent and NaBH4 is used as a reducing agent to prepare nano-Au particles.
[0073] According to the embodiments of the present application, there is also provided a nanomedicine with anti-cancer activity as described in any embodiment of the present application or a method for preparing the nanomedicine with anti-cancer activity as described in any embodiment of the present application in anti-cancer drugs.
[0074] According to an embodiment of the present application, an anticancer drug is also provided, which includes the nanodrug with anticancer activity described in any embodiment of the present application and a drug component loaded on the nanodrug, and the drug component includes a mixture of one or more drugs such as paclitaxel, camptothecin, doxorubicin, vinblastine, cisplatin, carboplatin, methotrexate, daunorubicin, interleukin, interferon, growth factor and tumor necrosis factor.
[0075] In the anticancer drug, the nano drug also has anticancer activity, and the drug component is loaded in the nano drug-carrying material. The drug component and the nano drug-carrying material work together to play an anticancer role and kill cancer cells.
[0076] The anticancer drug described in any embodiment of the present application can be used to treat a variety of diseases such as gastric cancer, ovarian cancer, breast cancer, liver cancer and bladder cancer. The anticancer drug can also be used to treat a variety of cancer diseases, and the type of active pharmaceutical ingredients in the anticancer drug can be changed to make it more suitable for the treatment of a variety of diseases.
[0077] Example 1 (1) Preparation of Ti3C2: First, Ti3AlC2 was dissolved in 10 mL HCl and soaked for 1 h for pretreatment, then 10 mL HF was added and stirred evenly, and the obtained mixed solution was transferred into a polytetrafluoroethylene reactor and heated to 80 °C for 10 h. The reaction liquid obtained after the reaction was centrifuged (speed of 5000 rpm, centrifugation time of 10 min), and the supernatant strong acid product was removed after centrifugation. 40 mL of deionized water was added to the precipitate in the centrifuge tube and mixed evenly. The precipitate was washed by ultrasonication for 20 min and centrifuged (speed of 6000 rpm, 10 min), and the pH value of the supernatant in the centrifuge tube was repeated several times until the pH value of the supernatant in the centrifuge tube was about 7.2. Add 40 mL of DMSO to the washed centrifuge tube (containing precipitate A) and mix well, transfer to a beaker and stir continuously at room temperature for 24 h, then ultrasonicate for 1 h, then centrifuge the reaction solution (speed 8000 rpm, 10 min), add 30 mL of deionized water and mix well, repeat washing and centrifugation (speed 8000 rpm, 10 min) three times, the obtained precipitate is Ti3C2, and freeze-drying is used to obtain Ti3C2 solid.
[0078] (2) Synthesis of nano-Au: 9.8 mg NaBH4 and 9.8 mg PVP were dissolved in 20 mL deionized water, mixed, heated and stirred until the liquid temperature reached 80 °C, and then 10 mL 0.0024 mol / L HAuCl4•4H2O solution was added. After reacting for 3 min, the heat source was removed, stirring was stopped and the mixture was cooled naturally to room temperature. The resulting solution was the nano-Au solution and was stored at 4 °C away from light. (3) Synthesis of MHF: 7 mg KMnO4 was dispersed in 1 mL deionized water, and 50 mg HSA was dispersed in 2 mL deionized water. After the solid was completely dissolved, the two solutions were mixed and stirred for 30 min. The pH value of the solution was adjusted to about 10 with 1 mol / mL NaOH. The reaction was carried out at room temperature for 3 min. The resulting solution (corresponding to mixed solution A) was dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The resulting solution (corresponding to mixed solution B) was freeze-dried to obtain MnO2-HSA solid. Dissolve 10 mg Fa in 10 mL DMSO and sonicate until Fa is completely dissolved. Then add 20 mg EDC•HCl, 20 mg NHS, and 50 µL TEA and stir for 30 min in the dark. Take 50 mg of the MnO2-HSA solid prepared in the above steps and disperse it in 25 mL of deionized water. Adjust the pH value of the solution to 10, slowly add Fa-NHS solution, stir for 24 h in the dark, then transfer the reaction solution (corresponding to mixed solution C) into a 5000 M dialysis bag, dialyze with PBS buffer solution (0.01 mol / L) and deionized water for three days to obtain mixed solution D, and freeze-dry to obtain MHF solid.
[0079] (4) Composite of Ti3C2, GOx, Au and MHF: Take 1 mL of the nano-Au solution prepared in step (2) and dilute it with deionized water to a final volume of 2 mL. Weigh 2 mg of Ti3C2 prepared in step (1) and dissolve it in 2 mL Au and dissolve it by ultrasonic. Then add 0.016 mg of GOx and stir it for 12 h after it is completely dissolved. Then add 0.016 mg of MHF prepared in step (2) to the solution, ultrasonicate it for 10 min and stir it for 24 h after it is completely dissolved. The obtained mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat this process three times. The Ti3C2 nano-drug carrier material, i.e., TGAM, is obtained by freeze drying.
[0080] Figure 1 The transmission electron microscope image of the Ti3C2-based nano drug-carrying material TGAM prepared in Example 1 shows that the structure of the prepared TGAM is a two-dimensional sheet, the Ti3C2 surface is wrapped by chain-like GOx, and Au and MHF nanoparticles are adsorbed on the outermost layer, with a size of about 600 nm. Fa wrapped on the surface of MnO2 has special cancer cell targeting. After Fa specifically recognizes the Fa receptor on the surface of cancer cells, the drug can be targeted into the cancer cells. In the acidic tumor microenvironment, MnO2, Au and GOx are released and play a role. At the same time, under the irradiation of 808 nm infrared near-field light, the temperature around the cells increases, and photothermal therapy and starvation therapy synergistically promote the apoptosis of cancer cells.
[0081] Effective drug loading can be achieved through Figure 2 and Figure 3 The infrared and ultraviolet spectra were verified. Figure 2 The horizontal axis is the wavelength of infrared light, and the vertical axis is the transmittance. Figure 2 It can be obtained that the infrared spectrum curve of the nano drug-carrying material TGAM prepared in Example 1 includes several relatively obvious troughs corresponding to the wavelengths of the horizontal coordinates of approximately 2997.8 cm -1 、1609.3 cm -1 、1385.6 cm -1 、1002.8 cm -1, which includes Ti3C2, GOx, Au and MHF. By comparing the infrared spectrum curves of Ti3C2, GOx, Au and MHF with the infrared spectrum curve of TGAM, it can be obtained that the nano drug-carrying material TGAM includes Ti3C2, GOx, Au and MHF.
[0082] Figure 3 The horizontal axis is the wavelength of ultraviolet light, and the vertical axis is the absorbance. Figure 3 It can be obtained that the characteristic ultraviolet absorption peaks of nano-Au and GOx involved in Example 1 are at 220 nm, the characteristic ultraviolet absorption peaks of MHF are at 220 nm and 277 nm, the ultraviolet absorption peak of nano-Au is at 504 nm, and the nano-drug carrier material TGAM has obvious ultraviolet absorption peaks near 220 nm, 277 nm and 500 nm, which fully confirms the effective loading of GOx, MHF and Au on the Ti3C2 surface.
[0083] Example 2 (1) Preparation of Ti3C2: First, Ti3AlC2 was dissolved in 10 mL HCl and soaked for 0.5 h for pretreatment, then 10 mL HF was added and stirred evenly, and the obtained mixed solution was transferred into a polytetrafluoroethylene reactor and heated to 100 °C for 10 h. The reaction liquid obtained after the reaction was centrifuged (speed of 5000 rpm, centrifugation time of 10 min), and the supernatant strong acid product was removed after centrifugation, and 20 mL of deionized water was added to the precipitate in the centrifuge tube and mixed evenly, and the precipitate was washed by ultrasonication for 20 min and centrifuged (speed of 6000 rpm, 10 min), and the pH value of the supernatant in the centrifuge tube was repeated several times until the pH value of the supernatant in the centrifuge tube was about 7.2. Add 20 mL of DMSO to the washed centrifuge tube and mix well, transfer to a beaker and stir continuously at room temperature for 24 h, then ultrasonicate for 1 h, then centrifuge the reaction solution (speed 8000 rpm, 10 min), add 30 mL of deionized water and mix well, repeat washing and centrifugation (speed 8000 rpm, 10 min) three times, the obtained precipitate is Ti3C2, and freeze-drying is used to obtain Ti3C2 solid.
[0084] (2) Synthesis of nano-Au: 9.8 mg NaBH4 and 9.8 mg PVP were dissolved in 20 mL deionized water, mixed and heated to 80 °C, and then 10 mL 0.003 mol / L HAuCl4•4H2O solution was added. After reacting for 3 min, the heat source was removed, stirring was stopped, and the mixture was cooled naturally to room temperature. The resulting solution was the nano-Au solution, which was stored at 4 °C away from light. (3) Synthesis of MHF: Disperse 7 mg KMnO4 in 1 mL deionized water and 50 mg HSA in 2 mL deionized water. After the solid is completely dissolved, mix and stir the two solutions for 30 min. Adjust the pH value of the solution to about 10 with 1 mol / mL NaOH. React at room temperature for 10 min. The resulting solution is dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The resulting solution is freeze-dried to obtain MnO2-HSA solid. Dissolve 10 mg Fa in 10 mL DMSO and sonicate until Fa is completely dissolved. Then add 20 mg EDC•HCl, 20 mg NHS, and 50 µL TEA and stir for 30 min in the dark. Take 50 mg of the MnO2-HSA solid prepared in the above steps and disperse it in 25 mL of deionized water. Adjust the pH value of the solution to 10, slowly add Fa-NHS solution, stir for 24 h in the dark, then transfer the reaction solution into a 5000 M dialysis bag, dialyze with PBS buffer solution (0.01 mol / L) and deionized water for three days respectively, and freeze-dry to obtain MHF solid.
[0085] (4) Composite of Ti3C2, GOx, Au and MHF: Take 1 mL of the nano-Au solution prepared in step (2) and dilute it with deionized water to a final volume of 2 mL. Weigh 2 mg of Ti3C2 prepared in step (1) and dissolve it in 2 mL of Au and dissolve it by ultrasonication. Then add 0.016 mg of GOx and stir it for 12 h after it is completely dissolved. Then add 0.016 mg of MHF prepared in step (2) to the solution, ultrasonicate it for 10 min and stir it for 24 h after it is completely dissolved. The obtained mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat this process three times. The Ti3C2 nano-drug carrier material, i.e., TGAM, is obtained by freeze drying.
[0086] Example 3 (1) Preparation of Ti3C2: First, Ti3AlC2 was dissolved in 10 mL HCl and soaked for 0.5 h for pretreatment, then 10 mL HF was added and stirred evenly, and the obtained mixed solution was transferred into a polytetrafluoroethylene reactor and heated to 80 °C for 8 h. The reaction liquid obtained after the reaction was centrifuged (speed of 5000 rpm, centrifugation time of 10 min), and the supernatant strong acid product was removed after centrifugation, and 40 mL of deionized water was added to the precipitate in the centrifuge tube and mixed evenly, and the precipitate was washed by ultrasonication for 20 min and centrifuged (speed of 6000 rpm, 10 min), and the pH value of the supernatant in the centrifuge tube was repeated several times until the pH value of the supernatant in the centrifuge tube was about 7.2. Add 40 mL of DMSO to the washed centrifuge tube and mix well, transfer to a beaker and stir continuously at room temperature for 24 h, then ultrasonicate for 1 h, then centrifuge the reaction solution (speed 8000 rpm, 10 min), add 30 mL of deionized water and mix well, repeat washing and centrifugation (speed 8000 rpm, 10 min) three times, the obtained precipitate is Ti3C2, and freeze-drying is used to obtain Ti3C2 solid.
[0087] (2) Synthesis of nano-Au: 4.9 mg NaBH4 and 4.9 mg PVP were dissolved in 20 mL deionized water, mixed, heated and stirred until the liquid temperature reached 80°C, and then 10 mL 0.0012 mol / L HAuCl4•4H2O solution was added. After reacting for 3 min, the heat source was removed, stirring was stopped and the mixture was cooled naturally to room temperature. The resulting solution was the nano-Au solution and was stored at 4°C away from light. (3) Synthesis of MHF: Disperse 7 mg KMnO4 in 1 mL deionized water and 50 mg HSA in 2 mL deionized water. After the solids are completely dissolved, mix the two solutions and stir for 30 min. -1 The pH value of the solution was adjusted to about 10 by NaOH, and the reaction was carried out at room temperature for 5 min. The obtained solution was dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The obtained solution was freeze-dried to obtain MnO2-HSA solid. Dissolve 5 mg Fa in 10 mL DMSO and sonicate until Fa is completely dissolved. Then add 10 mg EDC•HCl, 10 mg NHS, and 25 µL TEA and stir for 30 min in the dark. Take 50 mg of the MnO2-HSA solid prepared in the above steps and disperse it in 25 mL of deionized water. Adjust the pH value of the solution to 10, slowly add Fa-NHS solution, stir for 24 h in the dark, then transfer the reaction solution into a 5000 M dialysis bag, dialyze with PBS buffer solution (0.01 mol / L) and deionized water for three days respectively, and freeze-dry to obtain MHF solid.
[0088] (4) Composite of Ti3C2, GOx, Au and MHF: Weigh 2 mg of Ti3C2 prepared in step (1) and dissolve it in 2 mL of Au solution and dissolve it by ultrasonication. Then add 0.016 mg of GOx and stir it for 12 h after it is completely dissolved. Then add 0.016 mg of MHF prepared in step (2) to the solution and stir it for 24 h after it is completely dissolved by ultrasonication for 10 min. The obtained mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat this process three times. The Ti3C2 nano-drug carrier material, i.e., TGAM, is obtained by freeze drying.
[0089] Example 4 (1) Preparation of Ti3C2: First, Ti3AlC2 was dissolved in 10 mL HCl and soaked for 1 h for pretreatment, then 10 mL HF was added and stirred evenly, and the resulting mixed solution was transferred into a polytetrafluoroethylene reactor and heated to 80 °C for 10 h. The reaction liquid obtained after the reaction was centrifuged (speed of 5000 rpm, centrifugation time of 10 min), and the supernatant strong acid product was removed after centrifugation. 20 mL of deionized water was added to the precipitate in the centrifuge tube and mixed evenly. The precipitate was washed by ultrasonication for 20 min and centrifuged (speed of 6000 rpm, 10 min), and the pH value of the supernatant in the centrifuge tube was repeated several times until the pH value of the supernatant in the centrifuge tube was about 7.2. Add 20 mL of DMSO to the washed centrifuge tube and mix well, transfer to a beaker and stir continuously at room temperature for 24 h, then ultrasonicate for 1 h, then centrifuge the reaction solution (speed 8000 rpm, 10 min), add 30 mL of deionized water and mix well, repeat washing and centrifugation (speed 8000 rpm, 10 min) three times, the obtained precipitate is Ti3C2, and freeze-drying is used to obtain Ti3C2 solid.
[0090] (2) Synthesis of nano-Au: 9.8 mg NaBH4 and 9.8 mg PVP were dissolved in 20 mL deionized water, mixed and heated until the liquid temperature reached 80 °C, and then 10 mL of 0.0024 mol L -1HAuCl4•4H2O solution, remove the heat source after reacting for 3 minutes, stop stirring and cool naturally to room temperature. The resulting solution is the nano-Au solution, which should be stored at 4 ℃ away from light. (3) Synthesis of MHF: Disperse 7 mg KMnO4 in 1 mL deionized water and 50 mg HSA in 2 mL deionized water. After the solid is completely dissolved, mix and stir the two solutions for 30 min. Adjust the pH value of the solution to about 10 with 1 mol / mL NaOH. React at room temperature for 5 min. The resulting solution is dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The resulting solution is freeze-dried to obtain MnO2-HSA solid. Dissolve 10 mg Fa in 10 mL DMSO and sonicate until Fa is completely dissolved. Then add 20 mg EDC•HCl, 20 mg NHS, and 50 µL TEA and stir for 30 min in the dark. Take 50 mg of the MnO2-HSA solid prepared in the above steps and disperse it in 25 mL of deionized water. Adjust the pH value of the solution to 10, slowly add Fa-NHS solution, stir for 24 h in the dark, then transfer the reaction solution into a 5000 M dialysis bag, dialyze with PBS buffer solution (0.01 mol / L) and deionized water for three days respectively, and freeze-dry to obtain MHF solid.
[0091] (4) Composite of Ti3C2, GOx, Au and MHF: Take 1 mL of the nano-Au solution prepared in step (2) and dilute it with deionized water to a final volume of 2 mL. Weigh 1 mg of Ti3C2 prepared in step (1) and dissolve it in 2 mL of Au and dissolve it by ultrasonication. Then add 0.1 mg of GOx and stir it for 12 h after it is completely dissolved. Then add 0.02 mg of MHF prepared in step (2) to the solution, ultrasonicate it for 10 min after it is completely dissolved and stir it for 24 h. The obtained mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat this process three times. The Ti3C2 nano-drug carrier material, i.e., TGAM, is obtained by freeze drying.
[0092] Comparative Example 1 (1) Preparation of Ti3C2: First, Ti3AlC2 was dissolved in 10 mL HCl for soaking pretreatment, then 10 mL HF was added and stirred evenly, and the obtained mixed solution was transferred into a polytetrafluoroethylene reactor and heated to 80 °C for 10 h. The reaction liquid was centrifuged (speed of 5000 rpm, centrifugation time of 10 min), and the supernatant strong acid product was removed after centrifugation. 40 mL of deionized water was added to the precipitate in the centrifuge tube and mixed evenly. The precipitate was washed by ultrasonication for 20 min and centrifuged (speed of 6000 rpm, 10 min), and the pH value of the supernatant in the centrifuge tube was repeated several times until the pH value of the supernatant in the centrifuge tube was about 7.2. Add 40 mL of DMSO to the washed centrifuge tube and mix well, transfer to a beaker and stir continuously for 24 h at room temperature, then ultrasonicate for 1 h, then centrifuge the reaction solution (speed 8000 rpm, 10 min), add 30 mL of deionized water and mix well, repeat washing and centrifugation (speed 8000 rpm, 10 min) three times, the obtained precipitate is Ti3C2, and freeze-drying is used to obtain Ti3C2 solid.
[0093] (2) Synthesis of nano-Au: 9.8 mg NaBH4 and 9.8 mg PVP were dissolved in 20 mL deionized water, mixed, heated and stirred until the liquid temperature reached 80 °C, and then 10 mL 0.0024 mol / L HAuCl4•4H2O solution was added. After reacting for 3 min, the heat source was removed, stirring was stopped and the mixture was cooled naturally to room temperature. The resulting solution was the nano-Au solution and was stored at 4 °C away from light. (3) Synthesis of MnO2-HSA: 7 mg KMnO4 was dispersed in 1 mL deionized water and 50 mg HSA was dispersed in 2 mL deionized water. After the solid was completely dissolved, the two solutions were mixed and stirred for 30 min. The pH value of the solution was adjusted to about 10 with 1 mol / mL NaOH. The reaction was carried out at room temperature for 3 min. The obtained solution was dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The obtained solution was freeze-dried to obtain MnO2-HSA solid. (4) Composite of Ti3C2, GOx, Au and MnO2-HSA: Take 1 mL of the nano-Au solution prepared in step (2) and dilute it with deionized water to a final volume of 2 mL. Weigh 2 mg of Ti3C2 prepared in step (1) and dissolve it in 2 mL Au and dissolve it by ultrasonic. Then add 0.016 mg of GOx and stir it for 12 h after it is completely dissolved. Then add 0.016 mg of MHF prepared in step (2) to the solution, ultrasonicate it for 10 min and stir it for 24 h after it is completely dissolved. The obtained mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat three times. The Ti3C2 nano-drug carrier material, i.e. TGAM, is obtained by freeze drying.
[0094] Comparative Example 2 (1) Preparation of Ti3C2: Add 10 mL of hydrofluoric acid to a polytetrafluoroethylene beaker, slowly add 0.5 g of MAX-Ti3AlC2 to the beaker, and stir at room temperature for 72 h. Centrifuge the reaction liquid obtained after stirring (speed 4000 rpm, centrifugation time 10 min), remove the supernatant strong acid product after centrifugation, add 20 mL of deionized water to the precipitate in the centrifuge tube and mix evenly, repeat centrifugation (speed 6000 rpm, 10 min) until the pH value of the supernatant in the centrifuge tube is about 7.4. Add 20 mL of DMSO to the washed centrifuge tube and mix evenly, transfer to a beaker and continue stirring at room temperature for 24 h. Centrifuge the stirred reaction solution (speed 9000 rpm, 10 min), add 20 mL of deionized water and mix evenly, repeat washing and centrifugation (speed 9000 rpm, 10 min) three times, and the precipitate obtained is Ti3C2, which is freeze-dried to obtain solid Ti3C2.
[0095] (2) Synthesis of nano-Au: 9.8 mg NaBH4 and 9.8 mg PVP were dissolved in 20 mL deionized water, mixed, heated and stirred until the liquid temperature reached 80 °C, and then 10 mL 0.0024 mol / L HAuCl4•4H2O solution was added. After reacting for 3 min, the heat source was removed, stirring was stopped and the mixture was cooled naturally to room temperature. The resulting solution was the nano-Au solution and was stored at 4 °C away from light. (3) Synthesis of MHF: Disperse 7 mg KMnO4 in 1 mL deionized water and 50 mg HSA in 2 mL deionized water. After the solid is completely dissolved, mix and stir the two solutions for 30 min. Adjust the pH value of the solution to about 10 with 1 mol / mL NaOH. React at room temperature for 10 min. The resulting solution is dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The resulting solution is freeze-dried to obtain MnO2-HSA solid. Dissolve 10 mg Fa in 10 mL DMSO and sonicate until Fa is completely dissolved. Then add 20 mg EDC•HCl, 20 mg NHS, and 50 µL TEA and stir for 30 min in the dark. Take 50 mg of the MnO2-HSA solid prepared in the above steps and disperse it in 25 mL of deionized water. Adjust the pH value of the solution to 10, slowly add Fa-NHS solution, stir for 24 h in the dark, then transfer the reaction solution into a 5000 M dialysis bag, dialyze with PBS buffer solution (0.01 mol / L) and deionized water for three days respectively, and freeze-dry to obtain MHF solid.
[0096] (4) Composite of Ti3C2, GOx, Au and MHF: Take 1 mL of the nano-Au solution prepared in step (2) and dilute it with deionized water to a final volume of 3 mL. Weigh 1 mg of Ti3C2 prepared in step (1) and dissolve it in 2 mL of Au and dissolve it by ultrasonication. Then add 0.1 mg of GOx and stir it for 12 h after it is completely dissolved. Then add 0.02 mg of MHF prepared in step (2) to the solution, ultrasonicate it for 10 min after it is completely dissolved and stir it for 24 h. The obtained mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat this process three times. The Ti3C2 nano-drug carrier material, i.e., TGAM, is obtained by freeze drying.
[0097] Comparative Example 3 (1) Preparation of Ti3C2: First, Ti3AlC2 was dissolved in 10 mL HCl and soaked for 0.5 h for pretreatment, then 10 mL HF was added and stirred evenly, and the obtained mixed solution was transferred into a polytetrafluoroethylene reactor and heated to 80 °C for 6 h. The obtained reaction liquid was centrifuged (speed of 5000 rpm, centrifugation time of 10 min), and the supernatant strong acid product was removed after centrifugation, and 40 mL of deionized water was added to the precipitate in the centrifuge tube and mixed evenly, and the precipitate was washed by ultrasonication for 20 min and centrifuged (speed of 6000 rpm, 10 min), and the pH value of the supernatant in the centrifuge tube was repeated several times until the pH value of the supernatant in the centrifuge tube was about 7.2. Add 40 mL of DMSO to the washed centrifuge tube and mix well, transfer to a beaker and stir continuously for 24 h at room temperature, then ultrasonicate for 1 h, then centrifuge the reaction solution (speed 8000 rpm, 10 min), add 30 mL of deionized water and mix well, repeat washing and centrifugation (speed 8000 rpm, 10 min) three times, the obtained precipitate is Ti3C2, and freeze-drying is used to obtain Ti3C2 solid.
[0098] (2) Synthesis of MHF: Disperse 7 mg KMnO4 in 1 mL deionized water and 50 mg HSA in 2 mL deionized water. After the solid is completely dissolved, mix the two solutions and stir for 30 min. Adjust the pH value of the solution to about 10 with 1 mol / mL NaOH. React at room temperature for 10 min. The resulting solution is dialyzed in a 12000 M dialysis bag with deionized water for 24 h. The resulting solution is freeze-dried to obtain MnO2-HSA solid. Dissolve 10 mg Fa in 10 mL DMSO and sonicate until Fa is completely dissolved. Then add 20 mg EDC•HCl, 20 mg NHS, and 50 µL TEA and stir for 30 min in the dark. Take 50 mg of the MnO2-HSA solid prepared in the above steps and disperse it in 25 mL of deionized water. Adjust the pH value of the solution to 10, slowly add Fa-NHS solution, stir for 24 h in the dark, then transfer the reaction solution into a 5000 M dialysis bag, dialyze with 1xPBS solution and deionized water for three days respectively, and freeze-dry to obtain MHF solid.
[0099] (3) Composite of Ti3C2, GOx and MHF: Weigh 2 mg of Ti3C2 prepared in step (1) and dissolve it in 1 mL of deionized water. Then add 0.016 mg of GOx and stir for 12 h after it is completely dissolved. Then add 0.016 mg of MHF prepared in step (2) to the solution, sonicate for 10 min until it is completely dissolved and stir for 24 h. The resulting mixed solution is centrifuged at high speed (9000 rpm, 10 min), the supernatant is removed, and deionized water is added for washing. Repeat this process three times. The Ti3C2 nano-drug carrier material, namely TGM, is obtained by freeze drying.
[0100] Performance Testing 1. Dispersibility determination Take 1 mg Ti3C2 solid and dissolve it in 3 mL deionized water. The dispersion picture after ultrasonication for 10 min is as follows: Figure 4 As shown, the solution is not uniform in color and has obvious sedimentation.
[0101] 1 mg of GOx, Au solution and TGAM solid were dissolved in 3 mL of deionized water. The dispersion photos after ultrasonication for 10 min are shown in Figure 2. Figure 4 As shown, both the nano-Au solution and GOx have good water solubility and stability. Ti3C2 alone does not have good dispersibility. The dispersibility of Ti3C2 in water is significantly improved after being modified with GOx and nano-Au.
[0102] 2. Photothermal determination Aqueous solutions of Ti3C2, Au, and TGAM prepared in Example 1 were prepared, and 1 mL of each solution was added to a glass tube. After ultrasonic treatment for 10 min, the solution was cooled to room temperature. A temperature sensor was fixed at the bottom of the glass tube, and a thermocouple was connected. A near-infrared laser emitter at 808 nm was used to adjust the power to 1.5 W / cm by controlling the current. 2 Then start irradiation, and when the temperature rises to 25 ℃, start timing and record the temperature every 30 s.
[0103] like Figure 5 Shown at 1.5 W / cm 2 Under the irradiation of 808 nm infrared light, the temperature of ultrapure water remains almost unchanged. Nano-Au has weak photothermal conversion ability, while the temperature of 400 µg / mL Ti3C2 solution can rise to above 60 ℃ within 5 minutes, and the temperature of TGAM solution with the same concentration can rise to above 65 ℃, indicating that the prepared TGAM has good near-infrared absorption and photothermal performance. Loading nano-Au can improve the near-infrared absorption and photothermal performance of Ti3C2.
[0104] 3. Cytotoxicity Assay The carrier Ti3C2 prepared in Example 1 was prepared into solutions of different concentrations for cytotoxicity testing. The results are as follows: Figure 6 As shown in the figure, there was no significant change in the survival rate of A549 cells (human non-small cell lung cancer cells) and HeLa cells (HeLa cells) after being cultured with different concentrations of Ti3C2 for 24 h, indicating that the cytotoxicity of Ti3C2 is negligible.
[0105] 4. Anticancer activity assay The TGAM solution prepared in Example 1 with the same drug gradient concentration was tested for cytotoxicity. The results are as follows Figure 7 As shown in the figure, for the same concentration of TGAM drug, the survival rate of HeLa cells is lower than that of A549 cells. This may be because A549 cells cannot specifically recognize folic acid on the surface of TGAM, resulting in a lower drug concentration entering the cells than HeLa cells, which in turn leads to a higher cell survival rate.
[0106] Ti3C2 was co-loaded with GOx, Au and MHF, and HeLa cells were seeded in 96-well plates. After 24 hours, pure GOx, pure Ti3C2, TGM (Comparative Example 3) loaded with the same concentration of GOx and TGAM (Example 1), and TGAM (Example 1) + 808 nm laser (corresponding to Figure 8 TGAM+NIR in the sample was used as a parallel control, and the cell survival rate was tested after 24 hours. The results are as follows Figure 8As shown in the figure, compared with the starvation treatment of pure GOx, the introduction of Ti3C2, Au and MHF can significantly reduce the survival rate of cancer cells, which shows that photothermal therapy can achieve good synergy with starvation therapy. And the drug-loaded material loaded with nano-Au can reduce the survival rate of cancer cells.
[0107] In addition, although exemplary embodiments have been described herein, the scope includes any and all embodiments based on the present application with equivalent elements, modifications, omissions, combinations (e.g., various embodiments intersecting schemes), adaptations or changes. The elements in the claims are to be interpreted broadly based on the language adopted in the claims, and are not limited to the examples described in this specification or during the practice of this application, and the examples are to be interpreted as non-exclusive. Therefore, this specification and examples are intended to be considered as examples only, and the true scope and spirit are indicated by the following claims and the full scope of their equivalents.
[0108] The above description is intended to be illustrative rather than restrictive. For example, the above examples (or one or more schemes thereof) may be used in combination with each other. For example, a person of ordinary skill in the art may use other embodiments when reading the above description. In addition, in the above-mentioned specific embodiments, various features may be grouped together to simplify the present application. This should not be interpreted as an intention that a feature of an application that does not require protection is necessary for any claim. On the contrary, the subject matter of the present application may be less than all the features of an embodiment of a particular application. Thus, the following claims are incorporated herein in the specific embodiments as examples or embodiments, wherein each claim is independently a separate embodiment, and it is considered that these embodiments may be combined with each other in various combinations or arrangements. The scope of the present invention should be determined with reference to the appended claims and the full scope of equivalent forms granted by these claims.
[0109] The above embodiments are only exemplary embodiments of the present application and are not intended to limit the present invention. The protection scope of the present invention is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present invention within the essence and protection scope of the present application, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present invention.
Claims
1. A nano drug with anticancer activity, characterized in that: The nanomedicine comprises a titanium carbide carrier and targeted nanomaterials, nanogold and glucose oxidase loaded on the titanium carbide carrier. The titanium carbide carrier is a two-dimensional sheet structure. The targeted nanoparticle material comprises nanomanganese dioxide, human serum albumin and folic acid. Human serum albumin is modified on the surface of nanomanganese dioxide and connected to folic acid molecules to form spherical particles. Nanogold and manganese dioxide targeted nanoparticles are loaded on the surface of titanium carbide, and glucose oxidase is wrapped on the surface of the carrier.
2. The nano drug according to claim 1, characterized in that The particle size of the nano-gold is 5-10 nm.
3. The nano drug according to claim 1, characterized in that The mass ratio of titanium carbide, glucose oxidase, manganese dioxide-human serum albumin-folic acid, and nano-gold is 1-5 mg: 0.005-0.015 mg: 0.1-0.5 mg: 0.236 mg-4.74 mg.
4. A method for preparing the nano drug according to any one of claims 1 to 3, characterized in that: The preparation method comprises: The titanium carbide carrier is mixed with the nano-gold solution, glucose oxidase, the targeted nano-particle material and deionized water for reaction at room temperature to obtain the nano-drug-carrying material.
5. The preparation method according to claim 4, characterized in that: The mass volume ratio of titanium carbide, glucose oxidase, manganese dioxide-human serum albumin-folic acid, nanogold solution and deionized water is 1-5 mg: 0.005-0.015 mg: 0.1-0.5 mg: 0.5-10 mL: 0.5-10 mL, wherein the concentration of the nanogold solution is 0.002-0.004 mol / L.
6. The preparation method according to claim 4, characterized in that: The preparation method of the titanium carbide carrier includes: firstly, dissolving titanium aluminum carbide in hydrochloric acid for soaking pretreatment, then adding hydrofluoric acid and stirring evenly, transferring the obtained reactant into a polytetrafluoroethylene reactor, reacting for several hours under heating conditions, and separating the reaction product to obtain a precipitate A; mixing the precipitate A with dimethyl sulfoxide, and obtaining a titanium carbide carrier after reaction.
7. The preparation method according to claim 4, characterized in that: The preparation method of the targeted nanoparticle material comprises: mixing a potassium permanganate solution and a human serum protein solution, reacting under alkaline conditions to obtain a mixed solution A; dialyzing the mixed solution A with water to obtain a mixed solution B; drying the mixed solution B to obtain a composite material of manganese dioxide and human serum protein; mixing an aqueous solution of the composite material of manganese dioxide and human serum protein with a folic acid active ester solution to obtain a mixed solution C; dialyzing the mixed solution C with water to obtain a mixed solution D; and drying the mixed solution D to obtain the targeted nanoparticle material.
8. The preparation method according to claim 4, characterized in that: The preparation method of the nano gold solution comprises: mixing a chloroauric acid solution with a mixed solution E of sodium borohydride and polyvinyl pyrrolidone, and reacting under heating conditions to obtain the nano gold solution.
9. Use of the nano drug with anti-cancer activity according to any one of claims 1 to 3 or the method for preparing the nano drug with anti-cancer activity according to any one of claims 4 to 8 in anti-cancer drugs.
10. An anticancer drug, characterized in that: The anticancer drug comprises the nano drug with anticancer activity as described in any one of claims 1 to 3 and a drug component loaded on the nano drug, wherein the drug component comprises a mixture of one or more of paclitaxel, camptothecin, doxorubicin, vinblastine, cisplatin, carboplatin, methotrexate, daunorubicin, interleukin, interferon, growth factor and tumor necrosis factor drug materials.
